A major new initiative on the use of nanotechnology in medicine and healthcare has recently been launched by the UK government’s research councils; around £30 million (US$60 million) is expected to be available for large scale “Grand Challenge” style projects. The closing date for the first call has just gone by, so we will see in a few months how the research community has responded to this opportunity. What’s worth commenting on now, though, is the extent to which public engagement has been integrated into the process by which the call has been defined.
As the number of potential applications of nanotechnology to healthcare is very large, and the funds available relatively limited, there was a need to focus the call on just one or two areas; in the end the call is for applications of nanotechnology in healthcare diagnostics and the targeted delivery of therapeutic agents. As part of the program of consultations with researchers, clinicians and industry people that informed the decision to focus the call in this way, a formal public engagement exercise was commissioned to get an understanding of the hopes and fears the public have about the potential use of nanotechnology in medicine and healthcare. The full report on this public dialogue has just been published by EPSRC, and this is well worth reading.
I’ll be writing in more detail later both about the specific findings of the dialogue, and on the way the results of this public dialogue was incorporated in the decision-making process. Here, I’ll just draw out three points from the report: